Compare Gilead Sciences, Inc. (GILD) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Honeywell International Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Honeywell International Inc trades at $207.1 (market cap $65.48B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Honeywell International Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Honeywell International Inc for 90 Days on average.
| GILD | HON | |
|---|---|---|
Market Cap | $182.40B | $65.48B |
Volume | 4,469,821 | 2,047,782 |
Sector | Health | Industrials |
52-Week High | $155.80 | $248.79 |
52-Week Low | $116.74 | $188.14 |
Typical Hold Time | 111 Days | 90 Days |
Enterprise Value | $205.46B | $90.27B |
Dividend Yield | 2.23% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 8 and robust profitability margins. The company has beaten earnings estimates for three consecutive quarters and maintains a 66.7% analyst buy rating with a $259.25 consensus price target. Recent corporate developments include a $300 million refinery project win and quarterly dividend payments of $0.70 per share.
The outlook remains positive given HON's earnings momentum and strategic focus on automation post-spinoff, though technical weakness and rising debt-to-asset ratios pose near-term risks. Wall Street optimism is supported by strong profitability metrics and recent contract wins, while investors should monitor execution of the company's transformation strategy and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
